Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 14;17(10):1286-91.
doi: 10.3748/wjg.v17.i10.1286.

Treatment of pediatric refractory Crohn's disease with thalidomide

Cui-Fang Zheng  1 , Jia-Hua Xu, Ying Huang, Ying-Kit Leung
Affiliations

Treatment of pediatric refractory Crohn's disease with thalidomide

Cui-Fang Zheng et al. World J Gastroenterol. .

Abstract

Aim: To assess the efficacy and tolerability of thalidomide in pediatric Crohn's disease (CD).

Methods: Six patients with refractory CD received thalidomide at an initial dose of 2 mg/kg per day for one month, then increased to 3 mg/kg per day or decreased to 1 mg/kg per day, and again further reduced to 0.5 mg/kg per day, according to the individual patient's response to the drug.

Results: Remission was achieved within three months. Dramatic clinical improvement was demonstrated after thalidomide treatment. Endoscopic and pathological improvements were also observed after thalidomide treatment, which was well tolerated by all patients.

Conclusion: Thalidomide is a useful drug for pediatric refractory CD.

Keywords: Children; Inflammatory bowel disease; Thalidomide; Tumor necrosis factor-α.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean pediatric Crohn’s disease activity index during thalidomide treatment. aP < 0.0005. PCDAI: Pediatric Crohn’s disease activity index.
Figure 2
Figure 2
Endoscopy views of patients A, B, C, F before thalidomide treatment (A-D) and six months after thalidomide treatment (E-H).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Maeda K, Okada M, Yao T, Sakurai T, Iida M, Fuchigami T, Yoshinaga K, Imamura K, Okada Y, Sakamoto K. Intestinal and extraintestinal complications of Crohn’s disease: predictors and cumulative probability of complications. J Gastroenterol. 1994;29:577–582. - PubMed
    1. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12:4819–4831. - PMC - PubMed
    1. Gabalec L, Bures J, Sedová M, Valenta Z. [Quality of life of Crohn’s disease patients] Cas Lek Cesk. 2009;148:201–205. - PubMed
    1. Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther. 2002;16:1603–1609. - PubMed
    1. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699–703. - PMC - PubMed